Devroe Eric 4

What Happened

• Eric Devroe, Chief Operating Officer of Acrivon Therapeutics (ACRV), had 723 restricted stock units (RSUs) withheld by the company to satisfy mandatory tax withholding upon vesting. The withholding was reported as a disposition of 723 shares at $1.63 per share, totaling approximately $1,178. This is a routine tax-withholding event, not an open-market sale.

Key Details

• Transaction date: 2026-02-14
• Transaction type/code: F (shares withheld to satisfy tax withholding)
• Shares withheld/disposed: 723 at $1.63 each; total value ≈ $1,178
• Shares owned after transaction: Not specified in the provided filing
• Footnote: F1 — Shares were withheld by the issuer to satisfy mandatory tax withholding upon RSU vesting
• Filing: Report filed 2026-02-18; filing not flagged as late in the provided data

Context

• This was a tax-withholding (sell-to-cover) event tied to RSU vesting, which is administrative in nature and does not necessarily indicate the insider's view of the company. For retail investors, purchases are generally more informative about insider sentiment than routine withholdings like this.